1
Clinical Trials associated with [18F]UCB-2897Proof of Mechanism Study to Evaluate Binding of Alfa-synuclein by [18F]UCB-2897 in Participants With Parkinson's Disease or Multi-system Atrophy
The overall goal of this protocol is to:
Evaluate [18F]UCB-2897 as an α-synuclein targeted radiopharmaceutical.
The primary objective is:
• Confirm a specific α -synuclein signal with [18F]UCB-2897 in participants with PD and/or MSA relative to healthy volunteers
Secondary and exploratory objectives are:
* Determine the safety and tolerability of microdose [18F]UCB-2897
* Evaluate preliminary dosimetry of [18F]UCB-2897
Additional exploratory objectives are:
* Determine the pharmacokinetics / metabolism of [18F]UCB-2897
* Determine the optimal imaging protocol for [18F]UCB-2897
100 Clinical Results associated with [18F]UCB-2897
100 Translational Medicine associated with [18F]UCB-2897
100 Patents (Medical) associated with [18F]UCB-2897
100 Deals associated with [18F]UCB-2897